The Journal of Clinical Endocrinology & Metabolism · 2015 · 449 citations · 34 references
MedicinePharmacotherapyCardiovascular PharmacotherapyDiabetologyFalls PreventionDiabetes MellitusFracture PreventionFracture RiskMetabolic Bone DiseaseOsteoporosisSodium-glucose Cotransporter 2 InhibitorsBone Fracture RiskCardiovascular Disease IncidenceDrug Effects On Bone DensityFracture Risk From FallsPlasma Volume DepletionSodium-glucose CotransportSodium-glucose Cotransporter 2 InhibitionSodium-potassium-chloride Cotransporter Inhibition
CONTEXT: Canagliflozin is a sodium glucose cotransporter 2 inhibitor developed to treat type 2 diabetes mellitus (T2DM). OBJECTIVE: The purpose of this study was to describe the effects of canagliflozin on bone fracture risk. DESIGN AND SETTING: This was a randomized phase 3 study in patients with T2DM. PATIENTS AND INTERVENTIONS: Canagliflozin doses of 100 and 300 mg were evaluated in the overall population of patients from 9 placebo- and active-controlled studies (N = 10 194), as well as in separate analyses of a single trial enriched with patients with a prior history/risk of cardiovascular disease (ie, the CANagliflozin cardioVascular Assessment Study [CANVAS]; N = 4327) and a pooled population of 8 non-CANVAS studies (N = 5867). OUTCOME MEASURES: The incidence of adjudicated fracture adverse events (AEs), fall-related AEs, and volume depletion-related AEs was assessed. RESULTS: The incidence of fractures was similar with canagliflozin (1.7%) and noncanagliflozin (1.5%) in the pooled non-CANVAS studies. In CANVAS, a significant increase in fractures was seen with canagliflozin (4.0%) vs placebo (2.6%) that was balanced between the upper and lower limbs. The incidence of fractures was higher with canagliflozin (2.7%) vs noncanagliflozin (1.9%) in the overall population, which was driven by the increase of fractures in CANVAS. The incidence of reported fall-related AEs was low, but significantly higher with canagliflozin in CANVAS, potentially related to volume depletion-related AEs, but not significantly different in the pooled non-CANVAS studies and the overall population. CONCLUSIONS: Fracture risk was increased with canagliflozin treatment, driven by CANVAS patients, who were older, with a prior history/risk of cardiovascular disease, and with lower baseline estimated glomerular filtration rate and higher baseline diuretic use. The increase in fractures may be mediated by falls; however, the cause of increased fracture risk with canagliflozin is unknown.
34
Silvio E. Inzucchi, Richard M. Bergenstal, John B. Buse et al. · Diabetes Care · 2014 · 3.1K citations · Full text
William T. Cefalu, Lawrence A. Leiter, Kun‐Ho Yoon et al. · The Lancet · 2013 · 724 citations
Donald E. Kohan, Paola Fioretto, Weihua Tang et al. · Kidney International · 2013 · 646 citations · Full text
Kaj Stenlöf, William T. Cefalu, Kyung‐Ah Kim et al. · Diabetes Obesity and Metabolism · 2012 · 611 citations · Full text
Older Women With Diabetes Have a Higher Risk of Falls
Ann V. Schwartz, Teresa A. Hillier, Deborah E. Sellmeyer et al. · Diabetes Care · 2002 · 579 citations
Medicine, Geriatric Medicine, Aging +16